NCT05630651View on ClinicalTrials.gov

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

NARecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Hemophilia B
Interventions
GENETIC

ZS801

A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose level is 5.0×10\^12vg/kg.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER